RELAPSING-REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING-REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING-REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell treatment aims to calm MS Flare-Ups
Disease control OngoingThis study is testing whether adding a special immune cell therapy (called TolDec) to standard MS medications can better control the disease. The therapy involves taking a patient's own cells, modifying them in a lab, and reinfusing them to help calm the overactive immune respons…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Judit Pich • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
Blood test may guide better MS treatment decisions
Disease control OngoingThis study is for people with relapsing-remitting multiple sclerosis (MS) who have been stable on their current medication for at least a year. It aims to find out if switching to a different drug called ofatumumab is better at keeping the disease quiet than staying on their curr…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Can diet and exercise rival MS drugs? new study investigates
Disease control OngoingThis study aims to find out if a comprehensive lifestyle program—including a specific diet, exercise, and stress reduction—can be as effective as standard drug treatments for people newly diagnosed with multiple sclerosis (MS) or its early stage (CIS). It follows 44 participants …
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: NA • Sponsor: Terry L. Wahls • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Breakthrough trial tests promising MS drug in kids for first time
Disease control OngoingThis study compares two medications for children and teens with relapsing multiple sclerosis (MS). Researchers want to see if ocrelizumab (given by IV every 6 months) works better and is safer than fingolimod (taken as a daily pill) in controlling MS attacks. About 188 young peop…
Matched conditions: RELAPSING-REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC